Innao Pedrada, Pothisuwan Methasinee, Pengsa Prasit
Department of Obstetrics and Gynecology Sunprasittiprasong hospital Ubonratchathani, Thailand E-mail :
Asian Pac J Cancer Prev. 2016;17(9):4483-4486.
Despite the fact that ovarian cancer is the seventh most common cancer in women worldwide and the fth leading cause of cancer death, It is the most common cause of death due to reproductive cancers in Thailand where epithelial ovarian cancer (EOC) is commonly found. According to a Thai statistical analysis in 2010 by the Department of Medical Services, epithelial ovarian cancer was the sixth most common cancer in Thailand from 2001 to 2003.The incidence of 5.1 per 100,000 women per year. Human epididymis protein 4 (HE4) is a novo diagnostic tumor marker for EOC. The combination of HE4 and carcinoma antigen 125 (CA 125) is a tool for detecting epithelial ovarian cancer (EOC) better than using CA 125 alone. Therefore, the researcher is interested in HE4 does have a role to predict recurrent epithelial ovarian cancer.
The patients who had complete response after diagnosed with epithelial ovarian cancer by pathology, FIGO stage 3 or more had been treated through surgery and chemotherapy at the Sunpasitthiprasong Hospital from June 2014 until March 2016. The patients were followed up every three months, using tumor marker (CA 125, HE4,Carcinoma antigen 19-9) together with other checkup methods, such as rectovaginal examination, CXR every year and other imaging as indication. Afterwards, the data was analyzed for the ability of HE4 to detect recurrence of epithelial ovarian cancer.
In 47 patients in this study follow-up for 22 months after complete response treatment from surgery and chemotherapy in epithelial ovarian cancer, 23 had recurrent disease and HE4 titer rising .The patients with recurrent epithelial ovarian cancer demonstrated high levels of both HE4 and CA125 with sensitivity of 91.3% and 52.7% respectively, speci city of 87.5% and 95.6% and positive predictive values of 87.5% and 85.7% . HE4 can predict recurrent epithelial ovarian cancer (p-value=0.02242). Comparing HE4 and CA125 in predicting recurrent epithelial ovarian cancer HE4 had more potential than CA125 (p-value =0.8314).
The present study showed HE4 to have a role in predicting recurrent epithelial ovarian cancer and HE4 is potentially better than CA125 as a marker for this purpose.
尽管卵巢癌是全球女性中第七大常见癌症，也是癌症死亡的第五大主要原因，但在泰国，它是生殖系统癌症导致死亡的最常见原因，其中上皮性卵巢癌（EOC）很常见。根据泰国医疗服务部2010年的统计分析，2001年至2003年期间，上皮性卵巢癌是泰国第六大常见癌症。发病率为每年每10万名女性中有5.1例。人附睾蛋白4（HE4）是一种用于诊断EOC的新型肿瘤标志物。HE4与癌抗原125（CA 125）联合使用是一种比单独使用CA 125更好的检测上皮性卵巢癌（EOC）的工具。因此，研究人员对HE4在预测复发性上皮性卵巢癌中是否发挥作用感兴趣。
2014年6月至2016年3月期间，在Sunpasitthiprasong医院接受手术和化疗后确诊为上皮性卵巢癌且病理完全缓解、国际妇产科联盟（FIGO）分期为3期或更高的患者。每三个月对患者进行一次随访，使用肿瘤标志物（CA 125、HE4、癌抗原19-9）以及其他检查方法，如每年进行直肠阴道检查、胸部X光检查和其他影像学检查作为指征。之后，分析HE4检测上皮性卵巢癌复发的能力。
本研究中47例上皮性卵巢癌患者在手术和化疗后完全缓解治疗后随访22个月，其中23例出现疾病复发且HE4滴度升高。复发性上皮性卵巢癌患者的HE4和CA125水平均较高，敏感性分别为91.3%和52.7%，特异性分别为87.5%和95.6%，阳性预测值分别为87.5%和85.7%。HE4可以预测复发性上皮性卵巢癌（p值 = 0.02242）。在预测复发性上皮性卵巢癌方面比较HE4和CA125，HE4比CA125更具潜力（p值 = 0.8314）。
本研究表明HE4在预测复发性上皮性卵巢癌中发挥作用，并且作为用于此目的的标志物，HE4可能比CA125更好。
